TIGIT enhances CD4 + regulatory T‐cell response and mediates immune suppression in a murine ovarian cancer model
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
TIGIT enhances CD4
+
regulatory T‐cell response and mediates immune suppression in a murine ovarian cancer model
Authors
Keywords
-
Journal
Cancer Medicine
Volume 9, Issue 10, Pages 3584-3591
Publisher
Wiley
Online
2020-03-25
DOI
10.1002/cam4.2976
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Patterns of TIGIT Expression in Lymphatic Tissue, Inflammation, and Cancer
- (2019) Niclas C. Blessin et al. DISEASE MARKERS
- Cancer statistics, 2018
- (2018) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Selective FcγR Co-engagement on APCs Modulates the Activity of Therapeutic Antibodies Targeting T Cell Antigens
- (2018) Jeremy D. Waight et al. CANCER CELL
- Potent immunogenicity in BRCA1 -mutated patients with high-grade serous ovarian carcinoma
- (2018) Ying Dai et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Functional Anti-TIGIT Antibodies Regulate Development of Autoimmunity and Antitumor Immunity
- (2018) Karen O. Dixon et al. JOURNAL OF IMMUNOLOGY
- Regulatory T cells in autoimmune disease
- (2018) Margarita Dominguez-Villar et al. NATURE IMMUNOLOGY
- TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy
- (2017) William C. Dougall et al. IMMUNOLOGICAL REVIEWS
- TIGIT signalling pathway negatively regulates CD4+ T-cell responses in systemic lupus erythematosus
- (2017) Lie Mao et al. IMMUNOLOGY
- Changes in regulatory T cells in patients with ovarian cancer undergoing surgery: Preliminary results
- (2017) Meng Wu et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- The Association of Peripheral Blood Regulatory T-Cell Concentrations With Epithelial Ovarian Cancer
- (2017) Rikki A. Cannioto et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Programmed death-1 pathway blockade produces a synergistic antitumor effect: combined application in ovarian cancer
- (2017) Xinxin Zhu et al. Journal of Gynecologic Oncology
- TIGIT: A Key Inhibitor of the Cancer Immunity Cycle
- (2017) Nicholas A. Manieri et al. TRENDS IN IMMUNOLOGY
- TIGIT overexpression diminishes the function of CD4 T cells and ameliorates the severity of rheumatoid arthritis in mouse models
- (2016) Weigong Zhao et al. EXPERIMENTAL CELL RESEARCH
- Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer
- (2016) Ruea-Yea Huang et al. OncoImmunology
- TIGIT predominantly regulates the immune response via regulatory T cells
- (2015) Sema Kurtulus et al. JOURNAL OF CLINICAL INVESTIGATION
- Divergent Phenotypes of Human Regulatory T Cells Expressing the Receptors TIGIT and CD226
- (2015) Christopher A. Fuhrman et al. JOURNAL OF IMMUNOLOGY
- Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer
- (2015) Zhiqiang Guo et al. Journal of Translational Medicine
- RETRACTED ARTICLE: Targeted immune therapy of ovarian cancer
- (2014) Keith L. Knutson et al. CANCER AND METASTASIS REVIEWS
- PD-1 Blockade and OX40 Triggering Synergistically Protects against Tumor Growth in a Murine Model of Ovarian Cancer
- (2014) Zhiqiang Guo et al. PLoS One
- Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer
- (2013) Zhiqiang Guo et al. Journal of Translational Medicine
- Immunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancer
- (2013) Vincent Lavoué et al. Journal of Translational Medicine
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started